Li Ji-Jie, Zhang Hui-Qiong, Li Pei-Jun, Xin Zhi-Lan, Xi Ai-Qi, Ding Yue-He, Yang Zheng-Ping, Ma Si-Qing
Department of Respiratory Medicine, Qinghai Province Fourth People's Hospital, Xining 810000, Qinghai Province, China.
Qinghai Provincial Center for Disease Control and Prevention, Xining 810000, Qinghai Province, China.
World J Clin Cases. 2021 Aug 26;9(24):7032-7042. doi: 10.12998/wjcc.v9.i24.7032.
Coronavirus disease 2019 (COVID-19) is a serious infection caused by the new coronavirus severe acute respiratory syndrome coronavirus 2. The disease was first identified in December 2019 and has caused significant morbidity and mortality worldwide.
To explore the clinical characteristics and treatments for COVID-19 in the Qinghai-Tibetan Plateau Area in China.
We retrospectively analyzed the blood cell counts (neutrophils and lymphocytes), blood gas analysis, and thoracic computed tomography changes of patients from Qinghai Province before, during, and after treatment (January 23, 2020 to February 21, 2020). In addition, we summarized and analyzed the information of critical patients. All data were analyzed using SPSS 17.0 (SPSS Inc., Chicago, IL, United States). The quantitative and count variables are represented as the mean ± SD and (%), respectively.
The main symptoms and signs of patients with COVID-19 were fever, dry cough, cough with phlegm, difficulty breathing, and respiratory distress with a respiration rate ≥ 30 times/min, finger oxygen saturation ≤ 93% in the resting state, and oxygenation index less than 200 but greater than 100 (after altitude correction). Eighteen patients with COVID-19, of whom three were critical, and the others were in a mild condition, were included. The main manifestations included fever, dry cough, and fatigue. Three patients developed difficulty breathing and had a fever. They were eventually cured and discharged. Adjuvant examinations showed one case with reduced white cell count (6%) (< 4 × 10/L), six with reduced count of lymphocytes (33%) (< 0.8 × 10/L), and one with abnormal blood glucose level. All 18 patients were discharged, and no death occurred.
Our findings provide critical insight into assessing the clinical diagnosis and treatment for COVID-19 in the Tibetan plateau area.
2019冠状病毒病（COVID-19）是由新型冠状病毒严重急性呼吸综合征冠状病毒2引起的严重感染。该疾病于2019年12月首次被发现，并在全球范围内导致了显著的发病率和死亡率。
探讨中国青藏高原地区COVID-19的临床特征及治疗方法。
我们回顾性分析了青海省患者在治疗前、治疗期间及治疗后（2020年1月23日至2020年2月21日）的血细胞计数（中性粒细胞和淋巴细胞）、血气分析及胸部计算机断层扫描变化。此外，我们总结并分析了重症患者的信息。所有数据均使用SPSS 17.0（美国伊利诺伊州芝加哥市SPSS公司）进行分析。定量和计数变量分别表示为平均值±标准差和（%）。
COVID-19患者的主要症状和体征为发热、干咳、咳痰、呼吸困难，呼吸频率≥30次/分钟、静息状态下手指血氧饱和度≤93%以及氧合指数小于200但大于100（海拔校正后）。纳入18例COVID-19患者，其中3例为重症，其余为轻症。主要表现为发热、干咳和乏力。3例患者出现呼吸困难并伴有发热。他们最终治愈出院。辅助检查显示1例白细胞计数减少（6%）（<4×10⁹/L），6例淋巴细胞计数减少（33%）（<0.8×10⁹/L），1例血糖水平异常。18例患者均出院，无死亡病例。
我们的研究结果为评估青藏高原地区COVID-19的临床诊断和治疗提供了重要见解。
